Skip to content

Author

Harminder Singh

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non–small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials

The optimal first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for EGFR-mutant advanced non–small cell lung cancer (NSCLC) remains uncertain due to the availability of multiple generations of TKIs and limited head-to-head comparisons. A systematic review and network meta-analysis (NMA) o...

S. Mahato, S. Mudgal, Harminder Singh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.